<DOC>
	<DOCNO>NCT01290328</DOCNO>
	<brief_summary>The primary purpose study determine effect Epoetin Alfa ( Procrit ) change hemoglobin ( red blood cell count ) anemic kidney transplant recipient . The investigator hypothesize epoetin alfa raise hemoglobin .</brief_summary>
	<brief_title>Study Epoetin Alfa Treat Anemia After Kidney Transplantation</brief_title>
	<detailed_description>Anemia become increasingly recognize problem kidney transplant recipient , erythropoietin often prescribe treatment despite limited data regard outcome . Multiple clinical trial demonstrate correction anemia erythropoietin patient chronic kidney disease ( pre-transplant ) patient dialysis . No large clinical trial erythropoietin treatment do anemic kidney transplant recipient , however . The investigator hypothesize use treatment post-transplant anemia , Epoetin Alfa increase hemoglobin ( Hb ) . The investigator hypothesize Epoetin Alfa suppress pathogenic alloimmunity direct kidney transplant consequence , prevent immune-mediated injury thereby preserve renal function . Finally , investigator hypothesize treatment post-transplant anemia Epoetin Alfa also result improve patient-reported outcome ( quality life ) decrease left ventricular mass . In order test hypothesis , investigator propose randomize controlled trial Epoetin Alfa anemic kidney transplant recipient ( 9.0 &lt; Hb &lt; 11.0 ) . 100 study subject randomize either treatment Epoetin Alfa start dose 150 units/kg/week treatment ( 50 subjects/arm ) . The primary outcome change Hb measure CBC 6 week , 3 month , 6 month , 1 year enrollment . Secondary outcome measure include change renal function ( eGFR ) , change T cell phenotype , change patient-reported outcome ( SF-36 form ) , change leave ventricular mass ( cardiac MRI ) .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Kidney transplant recipient least 8 week posttransplant 3 . Mild moderate anemia , define 9.0 g/dL &lt; Hb &lt; 11 g/dL ) 4 . Estimated GFR ( MDRD ) &lt; 60 mL/min ( dialysis ) 5 . Transferrin saturation &gt; 20 % Ferritin &gt; 100 ng/mL 1 . History erythrocytestimulating agent ( ESA ) use previous 8 week 2 . Red blood cell transfusion previous 30 day 3 . History HIV/AIDS 4 . Nonfunctioning graft , define patient require chronic dialysis 5 . Hypersensitivity ESAs albumin 6 . Uncontrolled hypertension , define screen BP &gt; 180/100 7 . Newonset seizure ( diagnose within last 3 month ) seizure disorder uncontrolled medication ( breakthrough seizure medication ) 8 . History neoplasm except : adequately treat basal squamous cell carcinoma skin , solid tumor ( except primary CNS lymphoma ) treat curative therapy diseasefree 5 year . 9 . Pregnancy lactate 10 . Vitamin B12 deficiency ( Vit B12 &lt; 180 pg/mL ) 11 . Untreated folate deficiency ( folate &lt; 6.6 ng/mL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>alloimmunity</keyword>
</DOC>